Icecure Medical ( (ICCM) ) has issued an update.
IceCure Medical announced that its ProSense® Cryoablation technology was featured in six studies presented at the St. Gallen International Breast Cancer Conference held in Vienna, Austria, from March 12-15, 2025. The studies, which will be published in the journal ‘The Breast,’ highlight the system’s potential as a viable alternative to surgical tumor removal, particularly in early-stage breast cancer, and demonstrate its growing acceptance in the medical community. The studies suggest that ProSense® can effectively treat various breast cancer subtypes, including those in younger patients and those with triple-negative breast cancer, with a high rate of complete tumor ablation and minimal adverse effects, positioning IceCure as a leader in innovative cancer treatments.
More about Icecure Medical
IceCure Medical, listed on Nasdaq as ICCM, develops and markets advanced cryoablation therapy systems using liquid nitrogen for tumor destruction, focusing on breast, kidney, bone, and lung cancers. Their minimally invasive technology offers a safe and effective alternative to traditional surgical tumor removal, with their flagship ProSense® system marketed globally in regions including the U.S., Europe, and China.
YTD Price Performance: 23.58%
Average Trading Volume: 353,321
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $80.33M
For a thorough assessment of ICCM stock, go to TipRanks’ Stock Analysis page.